EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Iron overload in porphyria cutanea tarda



Iron overload in porphyria cutanea tarda



Haematologica 84(3): 248-253



Background and Objective. Porphyria cutanea tarda (PCT) is a disorder of porphyrin metabolism associated with decreased activity of uroporphyrinogen decarboxylase (URO-D) in the liver. The relevance of iron in the pathogenesis of PCT is well established: iron overload is one of the factors that trigger the clinical manifestations of the disease and iron depletion remains the cornerstone of therapy for PCT. A role for genetic hemochromatosis in the pathogenesis of iron overload in PCT has been hypothesized in the past but only after the recent identification of the genetic defect causing hemochromatosis has the nature of this association been partially elucidated. This review will outline current concepts of the pathophysiology of iron overload in PCT as well as recent contributions to the molecular epidemiology of hemochromatosis defects in PCT. Evidence and Information Sources. The authors of the present review have a long-standing interest in the pathogenesis, etiology and epidemiology of iron overload syndromes. Evidence from journal articles covered by the Science Citation Index(R) and Medline(R) has been reviewed and collated with personal data and experience. State of the Art and Perspectives. Mild to moderate iron overload plays a key role in the pathogenesis of PCT. The recent identification of genetic mutations of the hemochromatosis gene (HFE) in the majority of patients with PCT confirms previous hypotheses on the association between PCT and hemochromatosis, allows a step forward in the understanding of the pathophysiology of the disturbance of iron metabolism in the liver of PCT patients, and provides an easily detectable genetic marker which could have a useful clinical application. Besides the epidemiological relevance of the association between PCT and hemochromatosis, however, it remains to be fully understood how iron overload, and in particular the cellular modifications of the iron status secondary to hemochromatosis mutations, affect the activity of URO-D, and how the altered iron metabolism interacts with the other two common triggers for PCT and etiological agents for the associated liver disease: alcohol and hepatitis viruses. The availability of a genetic marker for hemochromatosis will allow some of these issues to be addressed by studying aspects of porphyrins and iron metabolism in liver samples obtained from patients with PCT, liver disease of different etiology and different HFE genotypes, and by in vitro studies on genotyped cells and tissues.

(PDF emailed within 0-6 h: $19.90)

Accession: 010885290

Download citation: RISBibTeXText

PMID: 10189391

DOI: 10.1046/j.1365-2133.2000.03874.x



Related references

Phlebotomy and iron-overload in porphyria cutanea tarda. Lancet 1(7607): 1184-1187, 1969

Mutations in the hemochromatosis gene, porphyria cutanea tarda, and iron overload. Hepatology 27(1): 289-291, 1998

Liver iron overload and deferoxamine treatment of porphyria cutanea tarda. Molecular Aspects of Medicine 11(1-2): 72-73, 1990

Rare cases of porphyria cutanea tarda associated with additional iron overload. Dermatologica 164(2): 127-132, 1982

Liver iron overload and desferrioxamine treatment of porphyria cutanea tarda. Dermatologica 182(1): 27-31, 1991

Iron overload and immunity a study in patients with porphyria cutanea tarda. Journal of Hepatology 5: S182, 1987

Porphyria cutanea tarda and beta-thalassaemia minor with iron overload. British Medical Journal 281(6243): 809-809, 1980

Serum ferritin in the assessment of liver iron overload and iron removal therapy in porphyria cutanea tarda. Journal of Laboratory and Clinical Medicine 107(1): 36-42, 1986

Hepatitis C virus antibodies and iron overload in patients with porphyria cutanea tarda. Hepatology 24(4 PART 2): 559A, 1996

Mutation of HLA-H is rare in Italian patients with porphyria cutanea tarda and iron overload. Journal of Hepatology 26(SUPPL 1): 173, 1997

Screening of patients with iron overload to identify hemochromatosis and porphyria cutanea tarda. Archives of Dermatology 133(9): 1098-1101, 1997

Porphyria cutanea tarda, hepatitis C infection, and iron overload in a patient on hemodialysis. American Journal of Medicine 106(2): 266-267, 1999

Porphyria cutanea tarda and beta-thalassaemia minor with iron overload in mother and daughter. British Medical Journal 280(6226): 1255-1255, 1980

Porphyria cutanea tarda associated with HFE C282Y homozygosity, iron overload, and use of a contraceptive vaginal ring. Journal of Community Hospital Internal Medicine Perspectives 6(1): 30380-30380, 2016

Coexistence of genetic hemochromatosis gh in italian patients with porphyria cutanea tarda pct and iron overload. Journal of Hepatology 16(SUPPL 1): S15, 1992